Financials Aelis Farma

Equities

AELIS

FR0014007ZB4

Pharmaceuticals

Real-time Euronext Paris Other stock markets 03:00:25 2024-05-03 EDT			5-day change	1st Jan Change
13 ^EUR	0.00%		0.00%	-0.76%

04-18	Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	CI
04-02	Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2022	2023	2024	2025
Capitalization ¹	169.1	170.7	170.7	-
Enterprise Value (EV) ¹	138.5	172	54.14	64.99
P/E ratio	-11.2 x	-9.56 x	-7.14 x	-6.02 x
Yield	-	-	-	-
Capitalization / Revenue	20.2 x	13.9 x	3.16 x	13.8 x
EV / Revenue	16.6 x	13.9 x	1 x	5.24 x
EV / EBITDA	-16.4 x	-11.6 x	1.39 x	-22.4 x
EV / FCF	-10.5 x	-8.86 x	11.8 x	-5.31 x
FCF Yield	-9.52%	-11.3%	8.5%	-18.8%
Price to Book	8.75 x	-40.6 x	1.2 x	1.63 x
Nbr of stocks (in thousands)	12,486	13,130	13,130	-
Reference price ²	13.54	13.00	13.00	13.00
Announcement Date	23-04-03	24-04-02	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net sales ¹	1.137	10.76	8.364	12.36	54.03	12.4
EBITDA ¹	-	-	-8.455	-13.5	38.87	-2.9
EBIT ¹	-	2.552	-8.525	-6.461	38.43	-3
Operating Margin	-	23.71%	-101.92%	-52.28%	71.13%	-24.19%
Earnings before Tax (EBT)	-	-	-	-	53.5	8.4
Net income ¹	-2.086	-	-14.29	-5.078	33.27	-5.367
Net margin	-183.47%	-	-170.83%	-41.09%	61.57%	-43.28%
EPS ²	-	-	-1.210	-1.360	-1.820	-2.160
Free Cash Flow ¹	-	-	-13.19	-17.7	4.6	-12.25
FCF margin	-	-	-157.68%	-198.88%	8.51%	-98.79%
FCF Conversion (EBITDA)	-	-	-	-	11.84%	-
FCF Conversion (Net income)	-	-	-	-	13.83%	-
Dividend per Share	-	-	-	-	-	-
Announcement Date	22-01-14	22-04-04	23-04-03	24-04-02	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S1	2023 S1
Net sales	4.251	-
EBITDA	-	-
EBIT	-	-
Operating Margin	-	-
Earnings before Tax (EBT)	-	-
Net income ¹	-10.35	-1.633
Net margin	-243.52%	-
EPS	-	-
Dividend per Share	-	-
Announcement Date	22-09-26	23-09-25

¹EUR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	-	-	-	-	-
Net Cash position ¹	-	-	30.6	13.9	117	106
Leverage (Debt/EBITDA)	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-13.2	-17.7	4.6	-12.3
ROE (net income / shareholders' equity)	-	-	-130%	-	-33.8%	-23%
ROA (Net income/ Total Assets)	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-
Book Value Per Share ²	-	-	1.550	-0.3200	10.80	7.970
Cash Flow per Share ²	-	-	-	-0.7200	6.330	0.3200
Capex ¹	-	-	-	-	-	0.15
Capex / Sales	-	-	-	-	-	1.21%
Announcement Date	22-01-14	22-04-04	23-04-03	24-04-02	-	-

¹EUR in Million²EUR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Aelis Farma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13 EUR

Average target price

20.67 EUR

Spread / Average Target

+58.97%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AELIS FARMA	-0.76%	183M
ELI LILLY AND COMPANY	+29.68%	681B
NOVO NORDISK A/S	+19.77%	556B
JOHNSON & JOHNSON	-4.35%	361B
MERCK & CO., INC.	+17.65%	325B
ABBVIE INC.	+3.77%	285B
ASTRAZENECA PLC	+13.64%	235B
NOVARTIS AG	+4.37%	199B
ROCHE HOLDING AG	-12.11%	189B
PFIZER, INC.	-3.79%	157B

Other Pharmaceuticals